New data from two early-stage clinical studies show that Novartis' Afinitor (everolimus) may overcome resistance to Herceptin (trastuzumab) in women with HER2-positive metastatic breast cancer. According to the Swiss drug major, these results support the initiation of a Phase III trial program to fully explore the potential of the agent, also known as RAD001, in breast cancer.
Two Phase I studies presented at this year's San Antonio Breast Cancer Symposium show that the combination of Afinitor plus Roche's Herceptin and weekly Taxol (paclitaxel) halted tumor growth in 77% of patients with HER2-positive metastatic breast cancer with documented resistance to Herceptin. In addition, the data demonstrated the first complete response in the trial.
Updated findings from the second Phase I study show promising anticancer activity for Afinitor in combination with Herceptin and Japanese drugmaker Kyowa Hakko Kogyo's Navelbine (vinorelbine) in heavily-pre-treated Herceptin-resistant patients with HER2-positive metastatic breast cancer. In the study, Afinitor plus Herceptin and Navelbine halted tumor growth in 62% of patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze